Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
7.45
+0.01 (0.13%)
At close: Jul 17, 2026, 4:00 PM EDT
7.49
+0.04 (0.54%)
After-hours: Jul 17, 2026, 7:58 PM EDT
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
129
Market Cap
452.92M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Prothena Corporation | 57.94M |
| Editas Medicine | 38.69M |
| Ovid Therapeutics | 7.12M |
| Adlai Nortye | 5.00M |
| Ocugen | 4.47M |
| Artiva Biotherapeutics | 251.00K |
KYTX News
- 25 days ago - Kyverna Therapeutics appoints Ritesh Srivastava chief legal, compliance officer - TheFly
- 25 days ago - Kyverna Therapeutics Appoints Ritesh Srivastava as Chief Legal and Compliance Officer, Adding Leadership Strength to Support Commercial-Stage Transition - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Kyverna Therapeutics presents updated COMPARE trial data at EULAR - TheFly
- 6 weeks ago - Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis - GlobeNewsWire
- 6 weeks ago - Kyverna Therapeutics Slides: Corporate presentation - Filings
- 7 weeks ago - Kyverna Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Kyverna Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts